SCHEMBL10102253

SCHEMBL10102253

COC(=O)c1c2c(c3ccccc3c1-c1ccccc1)OC(c1ccccc1)(c1ccc(C)cc1)C=C2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.45
LMNA P02545 3/20 0.40
ALDH1A1 P00352 6/20 0.38
KMT2A Q03164 3/20 0.38
POLB P06746 1/20 0.38
RAB9A P51151 1/20 0.37
MEN1 O00255 2/20 0.36
GAA P10253 1/20 0.36
AR P10275 1/20 0.36
PLA2G2A P14555 1/20 0.36
TP53 P04637 3/20 0.35
GPR84 Q9NQS5 1/20 0.35
HTT P42858 1/20 0.34
MAPK8 P45983 1/20 0.34
ATM Q13315 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MAPT P10636 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6931279 0.94 SMN1; SMN2 (0.46) SMN1; SMN2LMNAALDH1A1KMT2ARAB9A
SCHEMBL6169985 0.89 L3MBTL1 (0.43) SMN1; SMN2LMNAALDH1A1RAB9ATP53
SCHEMBL13464551 0.89 SMN1; SMN2 (0.38) SMN1; SMN2LMNAALDH1A1KMT2APOLB
SCHEMBL10102251 0.88 SMN1; SMN2 (0.37) SMN1; SMN2LMNAALDH1A1KMT2APOLB
SCHEMBL8978570 0.87 KDM4E (0.36) SMN1; SMN2LMNAALDH1A1KMT2APOLB
SCHEMBL29913570 0.87 KDM4E (0.36) SMN1; SMN2LMNAALDH1A1KMT2APOLB
SCHEMBL7608091 0.85 SMN1; SMN2 (0.41) SMN1; SMN2LMNAALDH1A1KMT2ARAB9A
SCHEMBL5645426 0.85 SMN1; SMN2 (0.35) SMN1; SMN2LMNAALDH1A1KMT2APOLB
SCHEMBL5107968 0.85 MAPK8 (0.41) SMN1; SMN2LMNAALDH1A1KMT2AMEN1
SCHEMBL8978679 0.84 SMN1; SMN2 (0.34) SMN1; SMN2LMNAALDH1A1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8308995-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-11-13 US disclosed
EP-2275418-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2012-10-17 EP disclosed
US-20120138876-A1 CHROMENE COMPOUND KASAI SOKO (JP) 2012-06-07 US disclosed
US-8147726-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-04-03 US disclosed
US-20110062396-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120138876-A1 CHROMENE COMPOUND CHRM1, CBX8, CBX7 SMN1; SMN2 1096/4885LMNA 602/4885ALDH1A1 1382/4885
US-20110062396-A1 CHROMENE COMPOUND CDYL, NR0B1, NR1H2 SMN1; SMN2 2922/4885LMNA 636/4885ALDH1A1 1987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.